Genfit S.A. (OTCMKTS:GNFTF) Short Interest Update

Genfit S.A. (OTCMKTS:GNFTF) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 5,500 shares, a growth of 1,000.0% from the October 31st total of 500 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Genfit Price Performance

Genfit stock remained flat at $5.55 during mid-day trading on Friday. The stock has a fifty day moving average of $5.48 and a 200 day moving average of $4.93. Genfit has a 1-year low of $2.95 and a 1-year high of $5.55.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.